David A. Spellman - 30 Sep 2021 Form 4 Insider Report for Akebia Therapeutics, Inc. (AKBA)

Role
SVP, CFO and Treasurer
Signature
/s/ Nicole R. Hadas, attorney-in-fact for David A. Spellman
Issuer symbol
AKBA
Transactions as of
30 Sep 2021
Net transactions value
$0
Form type
4
Filing time
01 Oct 2021, 16:06:55 UTC
Next filing
02 Mar 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKBA Employee Stock Option (Right to Buy) Award $0 +200,000 $0.000000 200,000 30 Sep 2021 Common Stock 200,000 $2.88 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.